Table 4.

Main riluzole pharmacokinetic parameters obtained in clinical studies conducted in healthy volunteers and patients with ALS

				PK results
Reference	Population	Administration	Dose	tmax (h)	Cmax (ng ml−1)	AUC (ng ml−1 h)
Leliboux et al. [13]	Healthy young	Oral/R	50 mg twice daily	0.75	271	1029
	Healthy elderly	Oral/R	50 mg twice daily	0.75	244	869
Groenveld et al. [14]	Patients	Oral/R	50 mg twice daily	–	231	48.7*
Leliboux et al. [7]	Healthy	Oral/S	25 mg	1.1	52	207
	Healthy	Oral/S	50 mg	0.9	180	537
	Healthy	Oral/S	100 mg	1.6	282	1195
	Healthy	Oral/R	25 mg	0.8	77	295
	Healthy	Oral/R	50 mg	0.8	137	654
	Healthy	Oral/R	100 mg	1.3	357	1483
Groenveld et al. [15]	Patients	Oral/R	50 mg twice daily	–	183	1473

AUC, area under the curve; t_max time to reach maximal concentration; C_max maximal concentration; λ_z elimination constant; t_1/2 elimination half-life; S, Single dose study; R: Repeated dose study.

^*AUC normalized to weight.